Company intelligence / Profile preview
Nanomerics
London, United Kingdomnanomerics.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 1
01
Overview
Nanomerics has completed a Phase 1 trial for OC134 in allergic conjunctivitis with positive tolerability results. Its MET platform has enabled the development of several candidates now in Phase 1 trials or outlicensed to partners such as Virpax Pharmaceuticals. The company is transitioning from preclinical to clinical-stage with its ophthalmology and CNS pipeline.
- Therapeutic areas
- OphthalmologyImmunologyNeurologyInfectious Diseases
- Modalities
- PeptidesSmall moleculeNanoparticleBiologic
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Virpax Pharmaceuticals (outlicensing of Envelta™, AnQlar™, NobrXiol™)US National Institutes of Health collaboration via Virpax on Envelta™ development
Beyond the preview
Go deeper on Nanomerics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanomerics.